Retinoic Acid Receptor Gamma (RARG) Genotyping
The RARG (Retinoic Acid Receptor Gamma) is a protein encoded by the RARG gene located at 12q13.13. The RARG protein belongs to the nuclear hormone family and acts as a regulator of the transcriptional function of the cell. Upon ligand interaction, the receptor binds to the retinoic acid response element (a type of hormone-responsive element) in the DNA at the promoter region and activates the transcription of proteins including topoisomerase II. The binding and unbinding of RARG regulates adequate protein transcription and is important for cell division and growth.
Clinically, RARG is affects the action of drugs such as anthracyclines (Doxorubicin, Daunorubicin, Epirubicin, Idarubicin, and Valrubicin) that interact with topoisomerase II. These drugs act by topoisomerase II poisoning, intercalating with DNA, generating reactive oxygen species (ROS), and ultimately damaging the DNA. Cancer cells with anthracycline-mediated DNA damage then undergo apoptosis.
Since anthracyclines act upon topoisomerase II, their optimum action is dependent on the availability of the enzyme. In individuals with variants in the RARG gene, there may be diminished function of RARG decreasing the transcription of topoisomerase II. In such individuals, the drug cannot act on its substrate and thus accumulates in cells resulting in cytotoxicity. Anthracycline-induced cardiotoxicity is a relatively common adverse effect with an incidence as high as 57%. The toxicity is potentially fatal and is clinically similar to congestive heart failure and left ventricular dysfunction. Individuals carrying the A-allele of the variant rs2229774 have increased risk for cardiotoxicity upon administration of anthracyclines.
Although cardiotoxicity can be monitored by monitoring left ventricular ejection fraction, and other tests, genetic testing for potential cardiotoxicity has been suggested before anthracycline administration. However, current evidence and concensus recommendations do not recommend genetic screening.
- Useful in predicting anthracycline-induced cardiotoxicity
- Aids in the selection of appropriate anti-cancer drugs
A positive result indicates the presence of variant rs2229724 in the RARG gene. The result is further interpreted as:
- Low risk: individuals with A/G allele. (Heterozygous)
- High risk: individuals with A/A allele. (Homozygous)
- In individuals with variants, dexrazoxane or liposomal encapsulated anthracycline preparations are safe to administer.
A negative result indicates the absence of variant rs2229724 in the RARG gene.
Negative (rs2229724 G/G indicated normal RARG functioning)
Whole blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: unstable
- Curr Oncol Rep. 2018 Apr 30;20(7):52. [PMID: 29713898]
- Pharmacogenomics. 2022 Apr;23(5):291-301. [PMID: 35147047]
- Cell Stem Cell. 2021 Dec 2;28(12):2076-2089.e7. [PMID: 34525346]
- Front Mol Biosci. 2019 Oct 24;6:114. [PMID: 31709264]
- Br J Clin Pharmacol. 2016 Sep;82(3):683-95. [PMID: 27197003]